阿仑膦酸钠治疗绝经后骨质疏松症的临床效果观察被引量：2

导出

摘要目的:对阿仑膦酸钠治疗绝经后骨质疏松症的临床效果进行观察。方法:选择十堰市郧阳区中医院2013年9月至2014年11月绝经后骨质疏松症患者86例作为研究对象。随机分为对照组和观察组,每组43例。观察组患者口服阿仑膦酸钠片,对照组口服钙尔奇,两组接受药物治疗的时间均为12个月。记录并观察两组患者在骨痛评分、治疗有效率、安全性指标、骨密质变化等。结果:两组患者接受治疗之后,骨痛等状况得到明显的缓解,骨痛评分下降,在Ward氏三角区等对骨密度的比较,观察组效果优于对照组,比较差异具有统计学意义(P<0.05)。两组患者在接受治疗的过程中未现出骨折现象。两组患者在服用药物之后肝肾功能变化、血常规等都维持在正常的范围之内。结论:通过口服阿仑膦酸钠治疗绝经后骨质疏松症的方式可以有效提高患者骨密度,改善患者生产质量,缓解骨痛,安全有效。

作者郭美江

机构地区十堰市郧阳区中医院

出处《深圳中西医结合杂志》 2017年第15期174-175,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

关键词阿仑膦酸钠钙尔奇绝经后骨质疏松症

分类号 R681 [医药卫生—骨科学]

引文网络
相关文献

参考文献3

1陈琳,游利,陈瑾瑜,潘凌,彭永德.应用阿仑膦酸钠治疗绝经后骨质疏松失效改用雷洛昔芬的疗效观察[J].中华骨质疏松和骨矿盐疾病杂志,2015,8(2):132-137. 被引量：8
2王燕,刘岩,李宝新,邸军,张大志,李玉坤.不同给药方案阿仑膦酸钠治疗绝经后骨质疏松的效果及不良反应的比较：6个月随访[J].中国组织工程研究与临床康复,2008,12(15):2895-2898. 被引量：19
3李梅,孟迅吾,邢小平,周学瀛,夏维波,胡莹莹,刘怀成.阿仑膦酸钠治疗37例绝经后骨质疏松症的疗效及观察[J].基础医学与临床,2003,23(3):302-305. 被引量：11

二级参考文献44

1Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of Alendronate: 7-year treaunent of postmenopausal osteoporotic women[J]. J Clin Endocrinol Metab, 2000,85:3109- 3115.
2Hernandez CJ, Boaupre GS, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during Alendronate treaunentE[J]. Bone, 2001,29:511- 516.
3Liberman UA, Weiss SR, Broll J, et al . Effect of oral Alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis[J]. N Engl J Med, 1995,333:1437- 1443.
4Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of Alendronate on fracture-related healthcare utilization and costs:the fracture intervention trial[J]. Osteoporos Int, 2001,12:654 - 660.
5Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of Alendronate on risk of fracture in women with existing vertebral fxacture[J]. Lancet, 1996,348:1535 - 1541.
6Watts NB, Jenkins DK, Visor JM, etal. Comparison of bone and total Alakine Phosphatase and bone mineral density in postmenopausal osteoporotic women treated with Alendronate [J].Osteoporos Int, 2001,12:279 - 288.
7Bauer DC, BlackD, Ensrud K, etal. Upper gastrointestinal tract safety profile of Alendronate : The fracture intervention trial[J]. Arch Intern Med, 2000,160:517- 525.
8Schacht E,Dukas L,Richy E Combined therapies in osteoporosis:bisphosphonates and vitamin D-hormone analogs.J Musculoskelet Neuronal Interact 2007;7(2):174-184.
9Ettinger MP,Gallagher R,MacCosbe PE.Medication persistence with weekly versus daily doses of orally administered bisphosphonates.Endocr Pract 2006; 12(5):522-528.
10Rosen CJ,Hochberg MC,Bonnick SL,et al.Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopansal osteoporosis:a randomized double-blind study.J Bone Miner Res 2005;20(1):141-151.